 |
市場調查報告書
商品編碼
1271206
躁鬱症治療市場，各藥物類別，各流通管道，各地區-規模，佔有率，展望，機會分析，2023年～2030年Bipolar Disorder treatment Market, By Drug Class, By Distribution Channel, And by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030 |
||||||
價格
簡介目錄
躁鬱症是一種終生疾病，可以透過適當的藥物治療來控制。用於控制躁鬱症症狀的藥物包括情緒穩定劑和非典型抗精神病藥。鋰與其他藥物等情緒穩定劑透過抑制躁狂和抑鬱等情緒波動來治療躁鬱症。患有躁鬱症的人會經歷異常強烈的情緒、不規律的睡眠模式、不規律的活動水準和情緒發作。躁鬱症是根據患者的症狀、家族史和生活史來診斷的。醫療保健提供者通常會進行心理健康評估以診斷躁鬱症。
市場上主要參與者日益採用合併、協議和合作等無機成長戰略，預計將推動預測期內的市場成長。
本報告對全球躁鬱症治療市場進行了深入分析，並提供了預測期(2023-2030年)的市場規模(百萬美元)和年複合成長率(CAGR%)，以 2022年為基準年。
目錄
>第1章 調查目的與前提條件
- 調查目的
- 前提條件
- 簡稱
第2章 市場展望
- 報告概要
- 市場定義和範圍
- 摘要整理
- 市場概述:各藥物類別
- 市場概述:各流通管道
- 市場概述:各地區
- Coherent Opportunity Map(COM)
第3章 市場動態，法規，趨勢分析
- 市場動態
- 促進因素
- 阻礙因素
- 市場機會
- 影響度分析
- 主要的焦點
- 產品的銷售
- 技術的進步
- PEST分析
- 法律規章情境
- M&A(合併、收購
第4章 躁鬱症治療的全球市場冠狀病毒(COVID-19)大流行造成的f的影響
- 經濟影響
- 關於COVID-19流行病學
- 供需的影響
第5章 躁鬱症治療的全球市場，各藥物類別，2017年～2030年
- 抗精神病藥
- 抗憂鬱症藥
- 心情穩定藥
- 抗焦慮藥另外
第6章 躁鬱症治療的全球市場，各流通管道，2017年～2030年
- 醫院內藥局
- 零售藥局
- 線上藥局
第7章 躁鬱症治療的全球市場:各地區，2017年～2030年
- 北美
- 美國
- 加拿大
- 南美
- 巴西
- 墨西哥
- 阿根廷
- 其他南美國家
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
- 中東地區
- GCC
- 以色列
- 其他中東地區
- 非洲
- 北非
- 中非
- 南非
第8章 競爭情形
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Allergan plc.
- Otsuka Holdings Co. Ltd.
- Johnson & Johnson
- Eli Lilly and Company
- GlaxoSmithKline plc.
- AstraZeneca Plc.
- Novartis International AG
- AbbVie Inc.
- Lundbeck A/S
- Minerva Neurosciences
- Sumitomo Dainippon Pharma Co., Ltd.
- Intra-Cellular Therapies Inc.
- Gedeon Richter Plc.
- Indivior PLC
第9章 Section
- 關於調查手法
- 關於出版社
簡介目錄
Product Code: CMI2605
Bipolar disorder is a lifelong disease, which can be managed with proper medication. The medications used to manage bipolar disorder symptoms include mood stabilizers and atypical antipsychotics. Mood stabilizers such as lithium and other drugs are used for the treatment of bipolar disorders by suppressing mood swings such as mania and depression. Cariprazine is an atypical antipsychotic drug indicated for the treatment of depressive episodes associated with bipolar I disorder in adults. Antidepressant medications are also prescribed to treat depressive episodes in bipolar disorder. Antidepressants combined with mood stabilizers are indicated to prevent the triggering of maniac episodes in patients with bipolar disorder. There is a sudden change in the mood of the patient and his/her ability to carry out daily tasks. There are four types of bipolar disorders: bipolar I, bipolar II, cyclothymic, and other specified and non-specified bipolar and related disorders. People suffering from bipolar disorder experience periods of unusually intense emotion, irregular sleep patterns, and activity levels, and mood episodes. Bipolar disorder is diagnosed based on the patient's symptoms, family history, and life history. The healthcare provider generally conducts a mental health evaluation for the diagnosis of bipolar disorder.
Market Dynamics
The increasing adoption of inorganic growth strategies such as mergers, agreements, and collaborations by key players operating in the market is expected to propel the market growth over the forecast period. For instance, in July 2019, Gedeon Richter plc, entered into an exclusive license agreement with Hikma Pharmaceuticals Plc. to commercialize cariprazine, a novel antipsychotic drug, in certain Middle East and North African or MENA markets. Moreover, earlier in August 2016, Gedeon RichterPlc. and Recordati signed an exclusive license agreement to commercialize cariprazine, a novel atypical antipsychotic drug in Western Europe, Algeria, and Tunisia.
Key features of the study:
- This report provides in-depth analysis of the global bipolar disorder treatment market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bipolar disorder treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study are Takeda Pharmaceutical Company Limited, Pfizer, Inc., Allergan plc, Otsuka Holdings Co. Ltd., Johnson & Johnson, Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca Plc, Novartis International AG, AbbVie Inc., H. Lundbeck A/S, Minerva Neurosciences, Sumitomo Dainippon Pharma Co., Ltd., Intra-Cellular Therapies Inc., Gedeon Richter Plc., and Indivior PLC
- Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global infection surveillance market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bipolar disorder treatment market
Detailed Segmentation:
- Global Bipolar Disorder Treatment Market, By Drug Class:
- Antipsychotics
- Antidepressants
- Mood Stabilizers
- Anti-anxiety Drugs and Others
- Global Bipolar Disorder Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Bipolar Disorder Treatment Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- North America
- Company Profiles
- Takeda Pharmaceutical Company Limited*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer, Inc.
- Allergan plc
- Otsuka Holdings Co. Ltd.
- Johnson & Johnson
- Eli Lilly and Company
- GlaxoSmithKline plc
- AstraZeneca Plc
- Novartis International AG
- AbbVie Inc.
- Lundbeck A/S
- Minerva Neurosciences
- Sumitomo Dainippon Pharma Co., Ltd.
- Intra-Cellular Therapies Inc.
- Gedeon Richter Plc.
- Indivior PLC
- Takeda Pharmaceutical Company Limited*
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Highlights
- Product Launch
- Technological Advancements
- PEST Analysis
- Regulatory Scenario
- Mergers and Acquisitions
4. Global Bipolar Disorder Treatment Market- Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Bipolar Disorder Treatment Market, By Drug Class, 2017 - 2030, (US$ Million)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Mood Stabilizers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Anti-anxiety Drugs and Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
6. Global Bipolar Disorder Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
7. Global Bipolar Disorder Treatment Market, By Region, 2017 - 2030, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Takeda Pharmaceutical Company Limited *
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Allergan plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Otsuka Holdings Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GlaxoSmithKline plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis International AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Minerva Neurosciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sumitomo Dainippon Pharma Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Intra-Cellular Therapies Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Gedeon Richter Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Indivior PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
9. Section
- Research Methodology
- About Us
